AR076875A1 - Anticuerpo contra receptor de la tirosina quinasa (anti-axl) - Google Patents
Anticuerpo contra receptor de la tirosina quinasa (anti-axl)Info
- Publication number
- AR076875A1 AR076875A1 ARP100101702A ARP100101702A AR076875A1 AR 076875 A1 AR076875 A1 AR 076875A1 AR P100101702 A ARP100101702 A AR P100101702A AR P100101702 A ARP100101702 A AR P100101702A AR 076875 A1 AR076875 A1 AR 076875A1
- Authority
- AR
- Argentina
- Prior art keywords
- axl
- antibodies
- typeosin
- antibody against
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un objetivo de la presente es disminuir la inmunogenicidad de los anticuerpos anti-AXL derivados de raton en los seres humanos por medio de la humanizacion de dichos anticuerpos. En la presente se proveen anticuerpos que se unen a una region específica en Anexelekto (AXL) y anticuerpos humanizados que se producen sobre la base de dichos anticuerpos. Los anticuerpos anti-AXL de la presente solicitud presentan una actividad antitumoral elevada y son utiles como agentes para disminuir el nivel de expresion de AXL, como agentes antitumorales y como agentes de diagnostico para el cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009118725 | 2009-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076875A1 true AR076875A1 (es) | 2011-07-13 |
Family
ID=43085106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101702A AR076875A1 (es) | 2009-05-15 | 2010-05-14 | Anticuerpo contra receptor de la tirosina quinasa (anti-axl) |
Country Status (22)
Country | Link |
---|---|
US (1) | US9340615B2 (es) |
EP (1) | EP2431393B1 (es) |
JP (1) | JP5669732B2 (es) |
KR (1) | KR20120024763A (es) |
CN (1) | CN102459344A (es) |
AR (1) | AR076875A1 (es) |
AU (1) | AU2010248365A1 (es) |
BR (1) | BRPI1011145A2 (es) |
CA (1) | CA2761891A1 (es) |
CL (1) | CL2011002877A1 (es) |
CO (1) | CO6460749A2 (es) |
CR (1) | CR20110646A (es) |
EC (1) | ECSP11011538A (es) |
IL (1) | IL216097A0 (es) |
MA (1) | MA33405B1 (es) |
MX (1) | MX2011012136A (es) |
PE (1) | PE20120562A1 (es) |
RU (1) | RU2011151069A (es) |
SG (1) | SG176074A1 (es) |
TW (1) | TW201041595A (es) |
WO (1) | WO2010131733A1 (es) |
ZA (1) | ZA201108526B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
PH12018501459A1 (en) * | 2007-09-26 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
AR069333A1 (es) * | 2007-11-15 | 2010-01-13 | Chugai Pharmaceutical Co Ltd | Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
BR112013032899A2 (pt) | 2011-06-22 | 2017-01-24 | Inserm Inst Nat De La Santé Et De La Rech Médicale | anticorpos anti-axl e utilizações dos mesmos |
CA2839508A1 (en) | 2011-06-22 | 2012-12-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-axl antibodies and uses thereof |
EP2748197A2 (en) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
US9717803B2 (en) * | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
CA2882272C (en) | 2012-08-24 | 2023-08-29 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc region variant |
EP2914630B1 (en) * | 2012-11-05 | 2021-03-03 | Pierre Fabre Medicament | Novel antigen binding proteins and their use as addressing product for the treatment of cancer |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
CN104341505A (zh) * | 2013-07-29 | 2015-02-11 | 西藏海思科药业集团股份有限公司 | 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体 |
TWI522099B (zh) | 2014-06-04 | 2016-02-21 | 中國醫藥大學 | 治療胰臟癌之醫藥配方及其應用 |
GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
AU2015286569B2 (en) | 2014-07-11 | 2021-04-15 | Genmab A/S | Antibodies binding AXL |
EP3229836B1 (en) * | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
JP6227191B1 (ja) | 2014-12-19 | 2017-11-08 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法 |
KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
EP3319993B1 (en) | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
SG11201805534TA (en) | 2016-01-13 | 2018-07-30 | Genmab As | Formulation for antibody and drug conjugate thereof |
GB201610902D0 (en) | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Il−8関連疾患の治療用又は予防用組成物 |
KR101909955B1 (ko) * | 2016-11-28 | 2018-10-19 | 재단법인 목암생명과학연구소 | 신규 항-에이엑스엘 항체 및 이를 포함하는 약학적 조성물 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
JP7268011B2 (ja) * | 2017-06-05 | 2023-05-02 | ヤンセン バイオテツク,インコーポレーテツド | 二重特異性抗体製造のための表面電荷を工学的に操作する方法 |
WO2019197506A1 (en) | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
CN110483639A (zh) * | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
CN109160941B (zh) * | 2018-09-29 | 2020-09-04 | 未名生物医药有限公司 | 蛋白序列17e11及其用途 |
MX2021007797A (es) * | 2018-12-28 | 2021-10-26 | Kyowa Kirin Co Ltd | Anticuerpo biespecifico que se une al receptor de transferrina (tfr). |
EP3946453A4 (en) * | 2019-03-29 | 2022-12-07 | Celldex Therapeutics, Inc. | ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE |
WO2021013746A1 (en) | 2019-07-19 | 2021-01-28 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
WO2021204713A1 (en) | 2020-04-08 | 2021-10-14 | Bergenbio Asa | Axl inhibitors for antiviral therapy |
GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
IL289525B2 (en) * | 2021-12-30 | 2023-03-01 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | Conjugated antibodies for cancer treatment |
CN117924510B (zh) * | 2024-03-21 | 2024-06-04 | 北京星基贝勤生物科技有限公司 | 靶向egfr和axl的双特异性抗体及其药物偶联物与应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0730646A1 (en) | 1993-11-23 | 1996-09-11 | Genentech, Inc. | PROTEIN TYROSINE KINASES NAMED Rse |
IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
RU2147443C1 (ru) | 1994-10-07 | 2000-04-20 | Чугаи Сейяку Кабусики Кайся | Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента |
EP0791359A4 (en) | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES |
US5977316A (en) | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
AU720232B2 (en) | 1996-07-19 | 2000-05-25 | Amgen, Inc. | Analogs of cationic proteins |
US6903194B1 (en) | 1996-09-26 | 2005-06-07 | Chungai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
CN100374159C (zh) | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
HUP0101160A2 (hu) | 1998-04-03 | 2001-08-28 | Chugai Seiyaku Kabushiki Kaisha | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6329511B1 (en) | 1998-12-01 | 2001-12-11 | Protein Design Labs, Inc. | Humanized antibodies to γ-interferon |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US7534605B2 (en) | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
JP2004511426A (ja) | 2000-05-03 | 2004-04-15 | ミュンヘン バイオテク アーゲー | 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬 |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
AU2002307037B2 (en) | 2001-04-02 | 2008-08-07 | Biogen Idec Inc. | Recombinant antibodies coexpressed with GnTIII |
UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
JP4063769B2 (ja) * | 2001-12-28 | 2008-03-19 | 中外製薬株式会社 | タンパク質安定化方法 |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
WO2004016740A2 (en) | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1608684A2 (en) | 2003-02-07 | 2005-12-28 | Protein Design Labs, Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US20050142133A1 (en) | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
JP4315982B2 (ja) | 2004-01-09 | 2009-08-19 | ファイザー インコーポレイティッド | MAdCAMに対する抗体 |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
EP1919950A1 (en) | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Optimized fc variants |
EP1799718A1 (en) | 2004-09-14 | 2007-06-27 | National Institute for Biological Standards and Control (NIBSC) | Vaccine |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
AU2005299716B2 (en) | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
US20090087478A1 (en) | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
WO2006076594A2 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
US8716451B2 (en) | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
SI1876236T1 (sl) | 2005-04-08 | 2014-11-28 | Chugai Seiyaku Kabushiki Kaisha | Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi |
EP1789435B1 (en) | 2005-09-12 | 2010-02-24 | Industry Foundation of Chonnam National University | A method for production of mature natural killer cell |
EP1928916A2 (en) | 2005-09-29 | 2008-06-11 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
WO2007089871A2 (en) | 2006-02-01 | 2007-08-09 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CN101495146B (zh) | 2006-04-07 | 2012-10-17 | 国立大学法人大阪大学 | 肌肉再生促进剂 |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
US20100291023A1 (en) | 2007-05-31 | 2010-11-18 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
CL2008002885A1 (es) | 2007-09-26 | 2010-07-02 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende |
PH12018501459A1 (en) | 2007-09-26 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
EP2196541B1 (en) | 2007-09-28 | 2012-11-07 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
ES2556214T3 (es) | 2007-11-12 | 2016-01-14 | U3 Pharma Gmbh | Anticuerpos para AXL |
US8898477B2 (en) * | 2007-11-12 | 2014-11-25 | Gemalto Inc. | System and method for secure firmware update of a secure token having a flash memory controller and a smart card |
AR069333A1 (es) * | 2007-11-15 | 2010-01-13 | Chugai Pharmaceutical Co Ltd | Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos |
SI2250279T1 (sl) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP2481752B1 (en) | 2009-09-24 | 2016-11-09 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
SA111320266B1 (ar) | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
-
2010
- 2010-05-14 AR ARP100101702A patent/AR076875A1/es unknown
- 2010-05-14 RU RU2011151069/02A patent/RU2011151069A/ru not_active Application Discontinuation
- 2010-05-14 MA MA34445A patent/MA33405B1/fr unknown
- 2010-05-14 SG SG2011084050A patent/SG176074A1/en unknown
- 2010-05-14 PE PE2011001964A patent/PE20120562A1/es not_active Application Discontinuation
- 2010-05-14 BR BRPI1011145A patent/BRPI1011145A2/pt not_active Application Discontinuation
- 2010-05-14 CA CA2761891A patent/CA2761891A1/en not_active Abandoned
- 2010-05-14 JP JP2011513382A patent/JP5669732B2/ja active Active
- 2010-05-14 CN CN2010800324176A patent/CN102459344A/zh not_active Withdrawn
- 2010-05-14 EP EP10774990.5A patent/EP2431393B1/en active Active
- 2010-05-14 US US13/320,317 patent/US9340615B2/en active Active
- 2010-05-14 TW TW099115414A patent/TW201041595A/zh unknown
- 2010-05-14 MX MX2011012136A patent/MX2011012136A/es unknown
- 2010-05-14 KR KR1020117029774A patent/KR20120024763A/ko not_active Application Discontinuation
- 2010-05-14 WO PCT/JP2010/058166 patent/WO2010131733A1/ja active Application Filing
- 2010-05-14 AU AU2010248365A patent/AU2010248365A1/en not_active Abandoned
-
2011
- 2011-11-02 IL IL216097A patent/IL216097A0/en unknown
- 2011-11-11 CO CO11153892A patent/CO6460749A2/es unknown
- 2011-11-15 CL CL2011002877A patent/CL2011002877A1/es unknown
- 2011-11-21 ZA ZA2011/08526A patent/ZA201108526B/en unknown
- 2011-12-02 CR CR20110646A patent/CR20110646A/es not_active Application Discontinuation
- 2011-12-15 EC ECSP11011538 patent/ECSP11011538A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO6460749A2 (es) | 2012-06-15 |
KR20120024763A (ko) | 2012-03-14 |
CL2011002877A1 (es) | 2012-05-25 |
WO2010131733A1 (ja) | 2010-11-18 |
TW201041595A (en) | 2010-12-01 |
CR20110646A (es) | 2012-02-09 |
JPWO2010131733A1 (ja) | 2012-11-08 |
IL216097A0 (en) | 2012-01-31 |
CN102459344A (zh) | 2012-05-16 |
JP5669732B2 (ja) | 2015-02-12 |
EP2431393A1 (en) | 2012-03-21 |
CA2761891A1 (en) | 2010-11-18 |
RU2011151069A (ru) | 2013-06-20 |
MX2011012136A (es) | 2012-04-10 |
WO2010131733A9 (ja) | 2012-01-19 |
EP2431393B1 (en) | 2018-05-02 |
EP2431393A4 (en) | 2013-07-17 |
BRPI1011145A2 (pt) | 2016-03-15 |
US9340615B2 (en) | 2016-05-17 |
ZA201108526B (en) | 2012-11-28 |
SG176074A1 (en) | 2011-12-29 |
AU2010248365A1 (en) | 2011-12-22 |
US20120121587A1 (en) | 2012-05-17 |
MA33405B1 (fr) | 2012-07-03 |
PE20120562A1 (es) | 2012-06-06 |
ECSP11011538A (es) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076875A1 (es) | Anticuerpo contra receptor de la tirosina quinasa (anti-axl) | |
UY35063A (es) | Composiciones y métodos que se dirigen a células estromales para el tratamiento del cáncer | |
CL2017000310A1 (es) | Anticuerpos anti tigit | |
EA201590171A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
CL2014001282A1 (es) | Uso de un inmunoconjugado de un anticuerpo dirigido contra el receptor del factor de crecimiento epidérmico (egfr) para el tratamiento del cáncer resistente al tratamiento dirigido contra egfr, donde el inmunoconjugado es un anticuerpo enlazado a un agente citotóxico. | |
EA201391602A1 (ru) | Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей | |
DOP2013000030A (es) | Compuesto heterociclico y su uso | |
HN2012001846A (es) | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos | |
CR20110686A (es) | Pirimidinonas como ihnibidores de pi3k | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
EA201590172A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
EA201890915A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
EA201791843A2 (ru) | Способы повышения эффективности folr1 терапии рака | |
MX340090B (es) | Analogos de spliceostatina. | |
CL2012000824A1 (es) | Anticuerpo que se une especificamente al epitopo que se une especificamente a un receptor epha2; conjugado de dicho anticuerpo que comprende un agente citotoxico derivado de un compuesto maitansinoide; metodo para preparar dicho conjugado; composicion farmaceutica. | |
PE20151672A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
MX352738B (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos. | |
GT201100023A (es) | Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos | |
AR077866A1 (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina | |
EA201491573A1 (ru) | Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
NI201300051A (es) | Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer. | |
TR201910959T4 (tr) | Elektromanyetik radyasyonun insan irisine uygulanması. | |
CR9253A (es) | Fijacion de la dosificacion de anticuerpos her | |
BR112012029917A2 (pt) | composições de nanotransportador com adjuvante desacoplado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |